First AD

Second AD

Breast Cancer

HER2-Positive Breast Cancer

Around the Practice

Previously recorded peer-to-peer panel discussions featuring authoritative insights, opinions, and perspectives on case presentations and audience engagement on important issues facing today's cancer care professionals.

Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer: Translating Evidence to Clinical Practice

Ruta Rao, MD, discusses her rationale for treating metastatic HER2+ breast cancer with a tucatinib-containing regimen based on data from the HER2CLIMB trial.

Tucatinib for Metastatic HER2+ Breast Cancer and Brain Metastases: Patient Selection

Clinical Case Presentation: A 36-Year-Old Woman with Breast Cancer and Brain Metastases

Treatment Options in the Frontline Setting for Metastatic HER2+ Breast Cancer

Second-Line and Third-Line Treatment Options for Metastatic HER2+ Breast Cancer

Treatment Options for HER2+ Breast Cancer After Progression on Tucatinib

Clinical Case Presentation: A 53-Year-Old Woman with Metastatic ER/PR+ HER2+ Breast Cancer and Brain Metastases

Neratinib for Metastatic HER2+ Breast Cancer and Brain Metastases

Leptomeningeal Metastases in HER2+ Breast Cancer

Novel Agents Under Evaluation for HER2+ Breast Cancer and Brain Metastases

Clinical Case Presentation: A 66-Year-Old Woman with ER+ HER2+ Invasive Ductal Carcinoma and Brain Metastases